Veeva and Sarah Cannon Research Institute Join Forces
In a groundbreaking move in the world of oncology research, Veeva Systems (NYSE: VEEV) has announced a strategic partnership with the Sarah Cannon Research Institute (SCRI). This collaboration is set to significantly improve the speed and efficiency of oncology clinical trials conducted across SCRI's extensive network of research sites.
Enhancing Clinical Trials with Veeva Clinical Platform
The SCRI has decided to implement the Veeva Clinical Platform, a comprehensive solution designed to streamline the management of clinical trials. With this platform, SCRI can unify its contract research organization (CRO) and site management organization (SMO) processes, allowing for a seamless data flow between clinical teams and research locations.
Yazhene Krishnaraj, SCRI’s chief information and digital officer, expressed enthusiasm about the integration of the Veeva platform into their operations. She stated that this collaboration empowers SCRI's clinical teams to deliver innovative therapies to patients more efficiently and accurately.
A Unified Approach to Oncology Research
The Veeva Clinical Platform aims to simplify and standardize trial processes, which significantly enhances the collaboration between investigators and clinical teams. With this modernized system, SCRI anticipates improved automation of key processes, resulting in a more efficient experience across all sites involved in the trials.
Jim Reilly, president of Veeva Development Cloud, shared his excitement regarding this unparalleled collaboration. He noted that the platform will act as a vital foundation for SCRI's operations, enabling them to conduct faster, more cost-effective trials while advancing innovation in oncology research.
About Veeva Clinical Platform
The Veeva Clinical Platform is designed to facilitate complete connectivity across all clinical operations and data applications. It encompasses a range of functionalities including clinical trial management systems (CTMS), electronic data capture (EDC), and remote trial supply management (RTSM). This integrated solution enhances the overall process of conducting clinical trials, promoting a smoother progression from study initiation to completion.
About Sarah Cannon Research Institute
As a leading global oncology research institution, the Sarah Cannon Research Institute focuses on conducting community-based clinical trials. Over the past thirty years, SCRI has made significant strides in advancing cancer therapies and has successfully conducted over 850 first-in-human trials. Their efforts have played a crucial role in the approval of numerous cancer treatments in recent years, showcasing their commitment to improving patient outcomes.
About Veeva Systems
Veeva is recognized as the global leader in cloud-based software solutions for the life sciences sector. With over 1,000 clients, ranging from some of the largest pharmaceutical companies to agile biotech firms, Veeva is dedicated to fostering innovation and ensuring customer success. As a Public Benefit Corporation, Veeva strives to balance the needs of its stakeholders while driving progress within the industry.
Frequently Asked Questions
What is the purpose of the Veeva and SCRI collaboration?
The collaboration aims to enhance the efficiency and speed of oncology clinical trials by utilizing the Veeva Clinical Platform.
What is the Veeva Clinical Platform?
The Veeva Clinical Platform is a comprehensive solution that integrates various clinical trial management processes for better collaboration and data flow.
How will this collaboration benefit patients?
By improving the clinical trial process, the collaboration ultimately aims to deliver innovative and effective cancer therapies to patients more rapidly.
How many locations does SCRI operate?
SCRI operates over 200 research sites across more than 20 states, allowing for widespread access to its clinical trials.
Is Veeva Systems involved in any other sectors?
Veeva primarily focuses on the life sciences industry, providing cloud software solutions to pharmaceutical and biotech companies worldwide.
